Jupiter Neurosciences Launches Nugevia™ Longevity Supplement Line to Diversify Revenue Streams

Jupiter Neurosciences Inc. (NASDAQ: JUNS) has launched Nugevia™, its direct-to-consumer longevity product line, marking a strategic shift to generate immediate revenue while continuing pharmaceutical development. The launch represents a significant milestone in the company's two-pronged approach of developing drugs for central nervous system disorders and rare diseases while building a consumer business to drive cash flow.

The scientifically backed longevity market, valued at $65 billion in 2023, is projected to reach $314 billion by 2030, with Jupiter Neurosciences estimating the combined mind, beauty, and energy addressable market at $8 trillion. Nugevia leverages the company's patent-protected JOTROL™ formulation, an enhanced orally administered resveratrol compound with eight years of pharmaceutical development behind it.

Christer Rosen, Chairman and CEO of Jupiter Neurosciences, stated that the launch represents the natural next step in translating science into real-world impact. The company's proprietary technology platform underpins both prescription drug development and the consumer offering, providing what Rosen describes as unmatched bioavailability and scientific credibility.

Nugevia's initial three formulations target mitochondrial support, mental clarity, and beauty from within, featuring precision-engineered intelligent stacking of synergistic compounds designed to enhance cellular resilience and support blood-brain barrier delivery. Nugevia GLO supports skin health from within, promoting cellular defense, collagen integrity, and hydration. Nugevia PWR focuses on mitochondrial health to support cellular energy, endurance, and recovery, while Nugevia MND protects and enhances cognitive function and overall brain health.

The company selected these initial product categories based on significant consumer interest and demand within the longevity market. Rosen emphasized the personal importance of the cognitive health product, noting his mother's death from Alzheimer's Disease and the former CFO's battle with Parkinson's Disease, stating the company is bringing what it believes is the best cognition product to market based on JOTROL pharmaceutical pre-clinical and clinical data.

To build brand awareness, Jupiter Neurosciences has named professional golfer Annika Sörenstam as its first brand ambassador. Sörenstam, who has won over 95 international tournaments including 72 LPGA titles and 10 major championships, will work with the company to promote Nugevia and its scientific backing. Rosen described Sörenstam as a powerful advocate for the mission to support healthy aging and optimal function at any life stage.

This direct-to-consumer approach represents a significant departure from traditional clinical-stage pharmaceutical company models, which typically take years to generate revenue while waiting for drugs to reach market. By leveraging its JOTROL technology for immediate consumer products, Jupiter Neurosciences aims to invigorate its business while continuing development of future pharmaceutical treatments.